All In Biotech

Drug Trial Radar · NCT03485209

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

350

Actual

Start

Jun 25, 2018

Primary completion

Mar 20, 2026

Study completion Mar 31, 2027

Sponsor

Sponsor type
Industry
Collaborators
Genmab; Merck Sharp & Dohme LLC
First posted
Apr 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. * In Part A, participants will receive tisotumab vedotin every 3 weeks (3-week cycles). * In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. * In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part D, participants will be given treatment on Day 1 of every 3-week cycle. * Participants in Part D will get tisotumab vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin * In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. * In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin. The objectives of the study have been achieved. Therefore, the study will transition to a long-term extension phase (LTEP). * In LTEP, participants still receiving clinical benefit based on the investigator's assessment and remaining on treatment may continue receiving treatment. * Participants will still receive tisotumab vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin

Conditions

  • Colorectal Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Exocrine Pancreatic Cancer
  • Carcinoma, Squamous Cell of Head and Neck

Interventions

  • tisotumab vedotinDrug

    Given into the vein (IV; intravenously)

  • pembrolizumabDrug

    200mg or 400mg given by IV

  • carboplatinDrug

    AUC 5mg/mL per minute or AUC 3.3mg/mL per minute given by IV

  • cisplatinDrug

    100mg/m\^2 given by IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed Objective Response Rate (ORR) (Parts A, B, C, D, E, F, and G)Time frame: Up to approximately 3 years

Locations

175 sites in 7 countries. Site status is shown where the registry gives one.

  • UCSD Medical Center - Encinitas

    Encinitas, California

  • UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)

    La Jolla, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • UCSD Koman Family Outpatient Pavilion

    La Jolla, California

  • UC San Diego/Moores Cancer Center

    La Jolla, California

  • UCSD Shiley Eye Institute

    La Jolla, California

  • University of California Davis Medical Center

    Sacramento, California

  • University of California, Davis Comprehensive Cancer Center

    Sacramento, California

  • UC San Diego Medical Center- Hillcrest

    San Diego, California

  • UC San Diego Health - Rancho Bernardo

    San Diego, California

  • Stanford Cancer Center South Bay

    San Jose, California

  • UCSD Medical Center - Vista

    Vista, California

  • Poudre Valley Hospital

    Fort Collins, Colorado

  • Eye Center of Northern Colorado

    Fort Collins, Colorado

  • Cancer Care & Hematology - Fort Collins

    Fort Collins, Colorado

  • Eye Center of Northern Colorado

    Fort Collins, Colorado

  • Cancer Care & Hematology - Greeley

    Greeley, Colorado

  • Cancer Care & Hematology - Loveland

    Loveland, Colorado

  • Simlow Cancer Hospitalat Yale-New Haven

    New Haven, Connecticut

  • Yale-New Haven Hospital- Yale Cancer Center

    New Haven, Connecticut

  • C/O Thomas Ferenez.RPh,BCOP,Smilow Cancer Hospital at Yale-New Haven

    New Haven, Connecticut

  • Family Focus Eye Care - Gainesville

    Gainesville, Florida

  • UF Health Davis Cancer Pavilion and Shands Med Plaza

    Gainesville, Florida

  • UF Health Shands Cancer Hospital

    Gainesville, Florida

  • UF Health Shands Hospital

    Gainesville, Florida

  • Family Focus Eye Care - Lake City

    Lake City, Florida

  • Moffitt Cancer Center McKinley Hospital

    Tampa, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Richard M Schulze Family Foundation Outpatient Center at McKinley Campus

    Tampa, Florida

  • Emory University Hospital Midtown

    Atlanta, Georgia

  • Emory University Hospital

    Atlanta, Georgia

  • Investigational Drug Service, Emory University Clinic

    Atlanta, Georgia

  • The Emory Clinic

    Atlanta, Georgia

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • Northwestern Medical Group

    Chicago, Illinois

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • UChicago Medicine - River East

    Chicago, Illinois

  • University of Chicago Medical Center

    Chicago, Illinois

  • Northwestern Medicine Cancer Center Kishwaukee

    DeKalb, Illinois

  • Northwestern Medicine Kishwaukee Hospital

    DeKalb, Illinois

Showing 40 of 175 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.